A Phase 4 interventional study of Indocyanine green in Deep Endometriosis and Recto Vaginal Node, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by University Hospital, Clermont-Ferrand · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 128 studies in Endometriosis with a site in France — 51 open to participants now, 56 under way, 1 of them phase 3. Endometriosis · France.
Among the 128 studies in Endometriosis with a site in France, this one is the 59th largest by enrollment of the 70 interventional ones that give a count, is one of 4 that started in 2017, is the only one in phase 4, and was the 21st registered.
924 studies on the registry are indexed under Endometriosis; 268 are open to participants now.
Browse Endometriosis studies →51 of the 128 studies in Endometriosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Limoges · Sites in France
Ages 18–50 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
Elsan · Sites in France
Ages 18–45 · Women only
ZIWIG · Sites in France
Ages 18–43 · Women only
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–40 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 180 Endometriosis studies recruiting now, 53 (29%) set no upper age limit and 125 (69%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
128 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 6 · Phase 4 1
First in 1990; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 67 across 542 interventional studies indexed under Endometriosis.
Median enrollment 91 across the 70 interventional studies, 133 across the 58 observational. Of the 54 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 128 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 6 studies filed under Endometriosis — fewer than ten, so there is no comparison to draw.
21 of the studies in Endometriosis with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06973603Institut National de la Santé Et de la Recherche Médicale, FranceExposure to Persistent Organic Pollutants and Severity of Endometriosis in the ComPaRe-Endometriosis Cohort | 2026-12 |
| NCT04704115University Hospital, LilleThe Therapy of Large Endometrioma | 2026-12 |
| NCT06392997ZIWIGEvaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | 2026-12 |
| NCT07864883University Hospital, Strasbourg, France3D Modeling of Deep Endometriosis From Pelvic MRI | 2026-12-27 |
| NCT04554602Assistance Publique - Hôpitaux de ParisFusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 128 studies in Endometriosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Indocyanine green is a dye, using in surgery to bring out the intraoperative evaluation of tissue perfusion.
After intravenous injection of indocyanine green, using a near infrared light, the vascularisation becomes fluorescent.
In endometriosis disease, the treatment of recto vaginal node can be complicated by rectovaginal fistula.
An abnormal vascularisation related to the surgery would be a risk factor of post operative fistulas.
The aim of this study is to evaluate the rectal and vaginal vascularisation during the treatment of a recto vaginal endometriosis nodule with rectal shaving, using indocyanine green fluorescence.
Investigators are going to inject, at the end of a rectal shaving, a bolus of 0,2mg/kg of indocyanine green after dilution (2,5mg/ml). With de SPIES system (KARL STORZ GmbH \& Co. KG, Tuttlingen, Germany), the vascularisation would be imediately fluorescent. Investigators are going to estimate the vascularization of the rectal serosa and mucosa where the nodule was located.
If a vaginal resection has been performed, investigators are going to estimate the vascularization of the vaginal scar.
To estimate de vascularization, investigators are going tu use a scale with a score between 0 and 4.
After the surgery, the post-operative follow-up with be the same as usual after a Rectal Shaving.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Indocyanine green
Use of Indocyanine Green during Rectal shaving by laparoscopy.
Per-operative evaluation of the rectum
Per-operative evaluation of the rectum after Shaving, using indocyanine green fluorescence, by transperitoneal and intra-rectal approach, and vaginal suture if there is an associated vaginal resection. A fluorescence score between 0 and 4 will be used, based on a Likert scale
Time frame: at day 1
Side effects after indocyanine green injection
Time frame: at day 1
Post operative complications
infections, abdominal abscess, abdominal hematoma, post operative fistula.
Time frame: at day 1
Ran from Aug 2017 to primary completion in Oct 2020, 37 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Feb 2019 → Oct 2020 and completion Feb 2019 → Nov 2020.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Indocyanine Green
University Hospital, Clermont-Ferrand →